drugset
drugset / Trial / NCT02844907

Regulation of Insulin Secretion by the GLP-1 Receptor

NCT02844907 ↗

Phase 4 Terminated 6 enrolled VA Office of Research and Development Durham VA Medical Center · collab
Non-randomizedCrossoverOpen-labelBasic science

Summary

AIM2: The purpose of Aim-2 of this study is to determine the role of basal GLP-1 action on the beta-cell response to insulin resistance. Healthy subjects will have fasting GLP-1 action determined with GLP-1r blockade before and after induction of experimental insulin resistance. The investigators hypothesize that fasting GLP-1 action will increase to compensate for experimental insulin resistance. AIM3: The purpose of Aim-3 of this study is to determine the role of basal GLP-1 action on fasting glucose regulation in lean, obese, pre-diabetic and type 2 diabetic (T2DM) subjects. A cross sectional study of age-matched subjects across the spectrum of glucose tolerance will be used to test the hypothesis that fasting GLP-1 action increases as beta-cell function declines.

Timeline

Start
2018-07-01
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Avexitide Peptide 750 unknown Other
Subject Dexamethasone Small molecule 4 mg —

Indications

No indication recorded.